NL990008I2 - CD#2#5 bindende molekulen. - Google Patents

CD#2#5 bindende molekulen.

Info

Publication number
NL990008I2
NL990008I2 NL990008C NL990008C NL990008I2 NL 990008 I2 NL990008 I2 NL 990008I2 NL 990008 C NL990008 C NL 990008C NL 990008 C NL990008 C NL 990008C NL 990008 I2 NL990008 I2 NL 990008I2
Authority
NL
Netherlands
Prior art keywords
antibodies
binding molecules
paticularly
immunoconjugates
prophylaxis
Prior art date
Application number
NL990008C
Other languages
English (en)
Other versions
NL990008I1 (nl
Original Assignee
Novartis Ag University College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26296798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL990008(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909005962A external-priority patent/GB9005962D0/en
Priority claimed from GB909019323A external-priority patent/GB9019323D0/en
Application filed by Novartis Ag University College filed Critical Novartis Ag University College
Publication of NL990008I1 publication Critical patent/NL990008I1/nl
Publication of NL990008I2 publication Critical patent/NL990008I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
NL990008C 1990-03-16 1999-04-01 CD#2#5 bindende molekulen. NL990008I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909005962A GB9005962D0 (en) 1990-03-16 1990-03-16 Improvements in or relating to organic compounds
GB909019323A GB9019323D0 (en) 1990-09-05 1990-09-05 Improvements relating to immunosuppression

Publications (2)

Publication Number Publication Date
NL990008I1 NL990008I1 (nl) 1999-06-01
NL990008I2 true NL990008I2 (nl) 1999-10-01

Family

ID=26296798

Family Applications (1)

Application Number Title Priority Date Filing Date
NL990008C NL990008I2 (nl) 1990-03-16 1999-04-01 CD#2#5 bindende molekulen.

Country Status (23)

Country Link
US (2) US6521230B1 (nl)
EP (1) EP0449769B1 (nl)
JP (1) JP2585475B2 (nl)
AT (1) ATE98655T1 (nl)
AU (1) AU635401B2 (nl)
CA (1) CA2038279C (nl)
CY (1) CY1977A (nl)
DE (2) DE19975033I2 (nl)
DK (1) DK0449769T3 (nl)
ES (1) ES2061216T3 (nl)
FI (3) FI103131B1 (nl)
HK (1) HK53797A (nl)
HU (2) HUT60768A (nl)
IE (1) IE65062B1 (nl)
IL (1) IL97545A (nl)
LU (1) LU90383I2 (nl)
MY (1) MY106161A (nl)
NL (1) NL990008I2 (nl)
NZ (1) NZ237434A (nl)
PL (1) PL170321B1 (nl)
PT (1) PT97034B (nl)
SA (1) SA92120358B1 (nl)
TW (1) TW213486B (nl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
JPH07509444A (ja) * 1991-11-26 1995-10-19 アルカーメス・インコーポレーテツド トランスフェリンセレプター特異的抗体−神経薬又は診断薬複合体の製造法
US6106834A (en) * 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
US6024957A (en) * 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) * 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
DE69835216T2 (de) 1997-07-25 2007-05-31 Nichia Corp., Anan Halbleitervorrichtung aus einer nitridverbindung
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
EP1100829B1 (en) * 1998-07-27 2007-09-05 Novartis AG Use of basiliximab in the treatment of rheumatoid arthritis or skin diseases
WO2000025816A1 (en) * 1998-10-30 2000-05-11 The University Of Miami Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound
US6406695B1 (en) 1998-10-30 2002-06-18 University Of Miami Treatment of hepatitis C by administration of anti-IL-2 receptor monoclonal antibody
GB9825632D0 (en) 1998-11-23 1999-01-13 Novartis Ag Organic compounds
FR2793691B1 (fr) * 1999-05-21 2003-10-03 Hippocampe Utilisation d'anticorps reconnaissant le recepteur de l'interleukine-2 dans la prevention et/ou le traitement des infections par les virus du sida
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
ES2314067T3 (es) * 2001-04-06 2009-03-16 University Of Bristol Uso de moleculas de enlace cd 25 en pacientes resistentes a los esteroides.
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
JP4966497B2 (ja) * 2002-11-15 2012-07-04 ゲンマブ エー／エス Ｃｄ２５に対するヒトモノクローナル抗体
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
JP2007531707A (ja) * 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
DK2270050T3 (da) * 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
KR20100135257A (ko) 2008-03-13 2010-12-24 바이오테스트 아게 질병 치료제
CN102027016A (zh) 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
RU2540018C2 (ru) 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
BR122022001178B1 (pt) 2009-10-26 2022-10-04 F. Hoffmann-La Roche Ag Método para a produção de uma imunoglobulina glicosilada e seu uso
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
US9580501B2 (en) 2011-12-16 2017-02-28 Synthon Biopharmaceuticals B.V. Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
CA2885340C (en) 2012-10-12 2016-11-08 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
MX2017006770A (es) 2014-11-25 2018-02-09 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepina y anticuerpo.
US9993452B2 (en) 2014-12-05 2018-06-12 Vireo Systems, Inc. Compositions and methods for treatment of inflammation
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
KR20190137847A (ko) 2017-04-20 2019-12-11 에이디씨 테라퓨틱스 에스에이 항-cd25 항체-약물 접합체와의 병용 요법
JP2021524449A (ja) 2018-05-23 2021-09-13 アーデーセー セラピューティクス ソシエテ アノニム 分子アジュバント
GB201811364D0 (en) 2018-07-11 2018-08-29 Adc Therapeutics Sa Combination therapy
JP7245358B2 (ja) * 2019-06-10 2023-03-23 山東博安生物技術股▲ふん▼有限公司 抗ｃｄ２５抗体及びその適用
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022221669A1 (en) 2021-04-15 2022-10-20 Kyverna Therapeutics, Inc. Methods and compositions for treating disease using targeted foxp3+cd4+ t cells and cellular suicide agents
CN114957473B (zh) * 2022-04-25 2023-05-16 苏州旭光科星抗体生物科技有限公司 一种对可溶性cd25蛋白含量检测的酶联免疫检测试剂盒
WO2024006961A1 (en) 2022-07-01 2024-01-04 Neoleukin Therapeutics, Inc. Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
GB2188941B (en) 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
EP0319333B1 (en) * 1987-12-02 1994-07-20 Becton, Dickinson and Company Method for the prevention of graft versus host disease
JPH02503867A (ja) * 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
DE3815472A1 (de) 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation

Also Published As

Publication number Publication date
ATE98655T1 (de) 1994-01-15
TW213486B (nl) 1993-09-21
US6383487B1 (en) 2002-05-07
LU90383I2 (fr) 1999-06-07
FI103131B (fi) 1999-04-30
CA2038279C (en) 1999-03-09
PT97034A (pt) 1991-10-31
JPH04316600A (ja) 1992-11-06
DE69100768T2 (de) 1994-05-11
IL97545A (en) 2000-06-29
IE910867A1 (en) 1991-09-25
EP0449769A1 (en) 1991-10-02
HK53797A (en) 1997-05-02
NL990008I1 (nl) 1999-06-01
DE69100768D1 (de) 1994-01-27
FI981799A (fi) 1998-08-21
US6521230B1 (en) 2003-02-18
FI19991788A (fi) 1999-08-23
EP0449769B1 (en) 1993-12-15
CA2038279A1 (en) 1991-09-17
HUT60768A (en) 1992-10-28
IE65062B1 (en) 1995-10-04
SA92120358B1 (ar) 2004-01-25
DE19975033I2 (de) 2007-01-04
FI911275A (fi) 1991-09-17
JP2585475B2 (ja) 1997-02-26
CY1977A (en) 1997-09-05
AU635401B2 (en) 1993-03-18
HU211885A9 (en) 1995-12-28
FI911275A0 (fi) 1991-03-14
AU7290991A (en) 1991-09-19
PL289436A1 (en) 1992-02-24
PT97034B (pt) 1998-07-31
DK0449769T3 (da) 1994-02-21
FI981799A0 (fi) 1998-08-21
HU910761D0 (en) 1991-09-30
FI104047B1 (fi) 1999-11-15
MY106161A (en) 1995-03-31
ES2061216T3 (es) 1994-12-01
FI104047B (fi) 1999-11-15
PL170321B1 (pl) 1996-11-29
FI103131B1 (fi) 1999-04-30
NZ237434A (en) 1992-08-26
IL97545A0 (en) 1992-06-21

Similar Documents

Publication Publication Date Title
NL990008I2 (nl) CD#2#5 bindende molekulen.
DE69429095D1 (de) Humanisierte antikoerper
DK0448057T3 (da) Monoklonalt antistof, der reagerer med en hidtil ukendt HLA-determinant på MHC klasse I-molekyler sa mt en fremgangsmåde til aktivereing af lymfocytter
GB2246781A (en) CD3 specific recombinant antibody
DK0626447T3 (da) Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
GR3025630T3 (en) Monoclonal antibody against human IgE
ES2179824T3 (es) Anticuerpos humanizados reactivos contra el antigeno gpiib/iiia.
KR890016165A (ko) 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
MY104917A (en) Monoclonal antibodies and methods for diagnosis of phytophora infection
DK0472498T3 (da) Monoklone antistoffer mod Leptosphaeria.
DK0513565T3 (da) Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse